AI
ZBIO

Atom Investors’s Zenas BioPharma ZBIO Stock Holding History

Atom Investors’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$943K Sell
37,149
-69,867
-65% -$1.39M 0.08% 371
2026
Q1 		$2.09M Buy
+107,016
New +$2.4M 0.15% 237

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Atom Investors's ZBIO Position: Q2 2026 in Review

Atom Investors reduced its Zenas BioPharma (ZBIO) stake by 65% in Q2 2026, selling an estimated $1.39M and leaving 37,149 shares worth $943K. The position accounts for 0.08% of the portfolio, ranked #371.

Atom Investors first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.09M in Q1 2026. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Atom Investors held 37,149 shares of Zenas BioPharma worth $943K as of Q2 2026.
  • Atom Investors sold 69,867 Zenas BioPharma shares in Q2 2026, an estimated $1.39M.
  • Zenas BioPharma made up 0.08% of Atom Investors's portfolio in Q2 2026, its #371 holding.
  • Atom Investors first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • Atom Investors's Zenas BioPharma position peaked at $2.09M in Q1 2026.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.